Clinical Trials Logo
  1. Home
  2. Hepatocarcinoma
  3. NCT05311319

HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma Clinical Trial

Official title:
Hepatic Artery Infusion Chemotherapy(HAIC) Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

Clinical Trial Summary

This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.

Clinical Trial Description

The high incidence of HCC recurrence following liver resection is a serious issue. However, no adjuvant therapy has been widely recognized at present. Interventional therapy and systemic drug therapy are common treatment methods and effective treatment for liver cancer. The combination of multiple drugs may reduce the recurrence in HCC patients with high-risk recurrence. TQB2450 is a humanized monoclonal antibody of programmed death-ligand1 (PD-L1), enabling T cells to restore immune activity and thus enhance the immune response. Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and proliferative signaling. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05311319
Study type Interventional
Source Fudan University
Contact Lu Wang, PhD
Phone +86-18121299357
Email w.lr@hotmail.com
Status Recruiting
Phase Phase 2
Start date January 11, 2022
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Terminated NCT03956940 - Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib N/A
Completed NCT03382327 - Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas N/A
Recruiting NCT03755739 - Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors Phase 2/Phase 3
Recruiting NCT06028724 - A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Not yet recruiting NCT03718078 - Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery N/A
Recruiting NCT05794048 - METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors N/A
Recruiting NCT04435977 - Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma Phase 2
Completed NCT04811898 - A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment Phase 1
Completed NCT05464706 - Study on the Quality of Life (QoL) After Liver Surgery N/A
Completed NCT01411579 - Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma N/A
Completed NCT02519075 - 11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
Recruiting NCT03356236 - Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation